Study of Diabetes' Risk Factors and Accelerated Aging According to Socio-economic Status in a Population From the North of France (PREVENDIAB)

April 19, 2024 updated by: Jean-Michel Lecerf, Institut Pasteur de Lille

Populations in precarious situations or with low socio-economic status have an increased risk of diabetes and accelerated aging. According to the population studied, the elements that can explain these health inequalities are not unequivocal and remain poorly known.

The north of France, particularly affected by socio-economic disparities, has a prevalence of diabetes among the highest in metropolitan France. This is why investigators want to study the clinical, biological, social and behavioural risk factors of the entry into diabetes and accelerated aging among a large population in the North of France.

This study aims to characterize the population (among which a majority (55%) suffers from precarious conditions) who come to carry out their health examination at the Pasteur Institute in Lille in order to study the risk factors to better explain these health inequalities.

This research consists of a main descriptive observational, cross-sectional study carried out on 2233 volunteers (main group) over 18 months, and a complementary analytical case-control study that will be offered to 216 participants (sub-group).

Study Overview

Detailed Description

Primary Objective : Assessment of Prevalence of Prediabetes and Diabetes by Socio-Economic Status

Primary efficacy endpoint : Fasting glucose value based on EPICES score :

Glycemia:

  • Normal: fasting glucose ≤ 1g/l
  • Prediabetes: fasting glucose >1 g/l and ≤1.25 g/l
  • Diabetes: fasting glucose >1.25 g/l

EPICES score: quintiles of score distribution (Q1 to Q5)

Secondary Objectives specific to the main group:

  • Characterize the population and analyze the risk factors (clinical, biological, socio-economic and behavioural) of diabetes and prediabetes in this population.
  • Study the level of biological ageing and factors associated with accelerated ageing.
  • Estimate the risk of (pre)diabetes and accelerated aging based on socio-economic profile.

Secondary Objectives specific to the sub-group:

  • Assess the impact of economic, social and cultural capital on health in terms of diabetes and accelerated aging.
  • Analyze the effect on diabetes and accelerated aging of the exposures assessed: body composition, physical activity, arterial rigidity, cognitive status, psychiatric disorders, fragility, pain.

Secondary endpoints specific to the main group: :

  • Prevalence ratio of diabetes and prediabetes calculated for:

    • Clinical, paraclinical parameters (Oral examination, Muscle strength,Advanced glycation products) and anthropometric parameters (medical history, height, weight, BMI, Waist and hip circumference, Neck circumference, body composition measurement, Systolic and diastolic blood pressure, Unipedal stance test).
    • Biological (blood and genetic).
    • Behavioural/environmental predictors: (socio-economic status, physical activity(RICCI GAGNON), diet(HDI), quality of life (MQLI), stress-anxiety(PSS), toxic habits, fragility(FRIED) ).
  • Assessment of the level of ageing

    • Biological Aging Marker: DNAmPhenoAge (DNA methylation phenotypic age)
    • Accelerated ageing: age regression DNAmPhenoAge on chronological age
    • Analysis of age-related parameters (inflammatory, renal, hormonal, body composition measurement, fragility, advanced glycation products, muscle strength) and correlation with methylation rate and DNAmPhenoAge.
  • Prevalence ratio of (pre)diabetes and accelerated aging according to socio-economic status

    • Evaluation of (pre)diabetes: fasting blood sugar
    • Accelerated Aging Assessment: DNAm PhenoAge
    • Social Status Assessment: EPICES Q1 to Q5 Score
    • Assessment of economic status: Income level

Secondary endpoints specific to the subgroup:

  • Risk (OR) of (pre)diabetes and accelerated aging according to social, economic, cultural and marital status

    • Evaluation of (pre)diabetes: fasting blood sugar
    • Accelerated Aging Assessment: DNAmPhenoAge
    • Socio-economic and cultural criteria

      • Social status (EPICES score)
      • Economic status (income)
      • Cultural status (semi-directive interview)
      • Professional status (educational level, socio-professional category, marital status)
  • Risk (OR) of (pre)diabetes and accelerated aging for assessed exposures:

    • Evaluation of (pre)diabetes: fasting blood sugar
    • Accelerated Aging Assessment: DNAmPhenoAge
    • Exposure Assessment

      • Arterial Stiffness Index
      • Body composition (mineral density, lean mass, fat mass) (DEXA test)
      • Insomnia Severity Index (ISI)
      • Cognitive Status (MOCA)
      • Physical Activity (GPAQ Questionnaire)
      • Alcohol consumption (FACE)
      • Psychiatric disorders (MINI)
      • Fragility (REFS score)
      • Pain Scale (EVA)

Study Type

Observational

Enrollment (Actual)

2014

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hauts De France
      • Lille, Hauts De France, France, 59019
        • Institut Pasteur de Lille

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Populations in precarious situations or with a low socioeconomic level have an increased risk of entering diabetes and aging accelerated. Depending on the populations studied, the elements that could explain these health inequalities are not unequivocal and are still badly known.

The Hauts-de-France region, particularly affected by disparities socio-economic, has one of the most prevalent diabetes high in the metropolis. This is why it's important to study the factors clinical, biological, social and behavioral risks of entry in diabetes and accelerated aging in a large population of North of France.

This study aims to characterize the population of the Centre's consultants of Health Examinations at the Institut Pasteur de Lille, of which a majority (55%) suffers from precarious conditions, in order to study the risk factors to better explain these health inequalities.

Description

Inclusion Criteria:

  • Adult, male or female
  • Consultant for the health prevention examination at the Examination Centre of Health of the Institut Pasteur of Lille
  • Available to follow the constraints generated by the study
  • Signature of the informed consent
  • Status of insured person in France

Exclusion Criteria:

  • Participation in another clinical study or in a period of exclusion from another study
  • Adult deprived of liberty or under judicial protection
  • Impediment to give the free and informed consent (understanding, persons under guardianship/curators, etc.)
  • Incompatible scheduling
  • Other reason (state of health or concomitant treatments,...) considered by the principal investigator or a qualified co-investigator not compatible with the proper conduct of the clinical study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Main group
Cross-sectional study
Biological analysis, Physical examination and questionnaires will be performed for all patients of the main group.
Sub group
Case control study
In addition to exams for the main group, there will be 2 additional examinations (bone densitometry and arterial stiffness) for the patients of the subgroup and others questionnaires.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fasting glucose value according to the level of precariousness
Time Frame: Day 0
Glycemia in g/L Level of precariousness given by EPICES score
Day 0

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence ratio of (pre)diabetes calculated for clinical, biological and behavioral/environmental explanatory variables
Time Frame: Day 0
In %
Day 0
Assessment of the level of accelerated ageing (DNAmPhenoAge)
Time Frame: Day 0
In units of years
Day 0
Prevalence ratio of (pre) diabetes and accelerated aging according to the socio-economic status
Time Frame: Day 0
In %
Day 0
Risk (odds Ratio) of (pre) diabetes and accelerated aging according to social, economic, cultural and professional status
Time Frame: Until Day 90
Without units
Until Day 90
Risk (odds Ratio) of (pre) diabetes and accelerated aging for assessed exposures
Time Frame: Until Day 90
Without units
Until Day 90

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Philippe Dr FROGUEL, PhD, PRECIDIAB
  • Study Director: Matthias Mr VANDESQUILLE, PhD, PRECIDIAB

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 14, 2021

Primary Completion (Actual)

March 31, 2024

Study Completion (Actual)

March 31, 2024

Study Registration Dates

First Submitted

December 14, 2021

First Submitted That Met QC Criteria

February 3, 2023

First Posted (Actual)

February 8, 2023

Study Record Updates

Last Update Posted (Actual)

April 22, 2024

Last Update Submitted That Met QC Criteria

April 19, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes

Clinical Trials on Biological analysis, Physical examination and Questionnaires

Subscribe